C
hildren and adolescents with inflammatory bowel disease (IBD) have an increased risk of reduced bone mineral density (BMD). [1] [2] [3] [4] We and others have previously shown that children and adolescents with IBD have low BMD, with almost 50% having BMD Z-scores ,21 SD and around 25% having BMD Z-scores ,22 SD, regardless of sex. [1] [2] [3] 5 There are, however, divergent data as to whether childhood-onset Crohn's disease (CD) and ulcerative colitis (UC) have different effects on bone development. Some studies have shown that children with CD have lower BMD than children with UC, 5, 6 whereas others did not find any difference. 1, 4 In parallel, several studies of adult patients with IBD have reported an increased risk of decreased BMD. 7, 8 Most of the adult studies did not find any difference between CD and UC, 7, 9 although a few found a lower BMD in CD cases than in UC cases. 8, 10 Recently, it has been reported that middle-aged male patients with IBD are more likely to have low BMD than corresponding female patients with IBD. 9, 11 A number of disease-related factors have been implicated in suboptimal bone mineralization in patients with childhood-onset IBD, including systemic inflammation per se, malnutrition, corticosteroid treatment, delayed puberty, growth retardation, low body mass index, and a sedentary lifestyle. 12, 13 However, it has been estimated that genetic and hereditary factors affect 60% to 80% of the development of BMD. 14 Bone mass accumulates during adolescence, with peak bone mass (PBM) being achieved in late adolescence in healthy individuals. 15 PBM has been reported to occur, irrespective of sex, about 5 years after the occurrence of peak height velocity (PHV) in both the lumbar spine and total hip, and about 7 years after PHV in the whole body, as estimated by BMD using dual-energy X-ray absorptiometry (DXA). 15, 16 There are only limited longitudinal data available regarding the development of BMD in the period from childhood into adulthood in patients with childhood-onset IBD. To the best of our knowledge, there is only 1 study that has prospectively studied the development of BMD in pediatric patients with IBD during this transition period. 17 In that study, Laakso et al 17 studied 47 patients with IBD with a mean age at follow-up of 19.7 years (range, 10.7-25.0 years) for a mean follow-up time of 5.1 years. The authors reported low BMD Z-scores at follow-up and no improvement of BMD Z-scores from baseline. 17 Similarly, a recent retrospective study conducted in young adults who had childhood-onset IBD and who had been assessed by DXA in young adulthood reported low BMD-Z scores (,21 SD) in around 50% of the patients. 18 We have previously reported that pediatric patients with IBD in late adolescence (age range, 17-19 years) have low BMD Z-scores, although surprisingly they tended to improve their BMD values in the lumbar spine after 2 years of follow-up. 1 This observation raises the question as to whether the accumulation of bone mass beyond the normally expected age for achieving PBM occurs in patients with childhood-onset IBD.
The primary aim of our follow-up study was to investigate whether young adults with childhood-onset IBD have compromised bone mineralization and to correlate their BMD data to anthropological measures and disease subcategories. A secondary aim was to examine whether patients with childhood-onset IBD have the potential to improve their BMD into young adulthood beyond the expected age for attaining PBM, as our previous data have indicated.
PATIENTS AND METHODS

Patients
In this prospective, longitudinal cohort study of patients from the Gothenburg region in western Sweden, a total of 74 young adult patients with childhood-onset IBD were followed for a mean time of 8.4 years (Fig. 1) . As previously described, 1,2 166 patients were eligible from the only two centers responsible for the diagnosis, treatment, and follow-up of childhood-onset IBD in the catchment area, representing therefore the entire clinical spectrum of childhood-onset IBD, including patients with mild, moderate, and severe disease. These two centers are The Queen Silvia Children's Hospital at Sahlgrenska University Hospital, Gothenburg, and the Department of Pediatrics at Södra Älvsborgs Hospital, Borås. In total, 144 of the 166 initially eligible patients participated in the baseline measurement, which was conducted between years 2003 and 2005. Of those 144 patients, 126 participated in the first 2-years follow-up measurement between years 2005 and 2007. In the second follow-up, measurements of 74 young adult patients with IBD were taken between years 2012 and 2015. Thus, a total of 52 of 126 patients did not participate in the second follow-up, mainly due to relocation out of the area, unwillingness to participate, or failure to establish contact with some previous participants (Fig. 1) . These nonparticipants did not differ significantly at the first follow-up visit from the participants included in the second follow-up with regards to mean age ( 
Data Collection
Clinical data were collected from electronic medical records. Data on age, sex, height, weight, disease subcategory (CD, UC, and IBD-unclassified [IBD-U]), disease duration, age at disease onset, medical treatment (prednisolone, 5-aminosalicylic acid , azathioprine, methotrexate, and tumor necrosis factor-a inhibitors as biological therapy), and surgical treatment (any intestinal resection or fistula operation) were registered. Medical treatment was recorded as the ongoing treatment at the second follow-up and previous medication since the time of diagnosis. No other biological medication was used in these patients. For 3 of the patients, the subcategory diagnosis changed from IBD-U to UC between the first and second follow-up visits. No other subcategory changes were seen during this period. Bone age was estimated at baseline by a radiograph of the left wrist, according to the method of Greulich and Pyle, as previously published by our group. 2 
Height and PHV
Height was measured to the nearest 0.5 cm using a wallmounted stadiometer. Weight was measured to the nearest 0.1 kg using the same calibrated scale for all patients at each study visit. But the scales differ between the study visits, i.e., baseline, first, and second follow-up visits. Parental data have previously been reported by our research team, 19 and in this study, we used parental height data for estimation of the target heights (THs) of our patients.
The estimate of TH was based on data from a Swedish population-based TH prediction study. 20 Average parental height (mother and father, x 1 ) data were available for 66 patients; TH was calculated as 37.85 + 0.75*x 1 for females and 45.99 + 0.78*x 1 for males. Calculations of TH were not possible in 8 patients due to insufficient parental height information. Growth restriction was defined as a height Z-score below 22 SD.
Detailed growth and weight charts from birth until 18 years of age were available for 43 patients, with age at PHV being derived from each individual growth curve for which there was sufficient information on all 3 growth phases, and fitting the Infancy-Childhood-Puberty model by minimizing the sum of the squares using a modification of the Levenberg-Marquardt algorithm. 21 To estimate the PHV, 2 or more measurements during the critical "peri-PHV" period were needed, not more than 2 years from PHV and not more than 3 years from each other. PHV is generally believed to be reached within 2 years of the onset of puberty. 21, 22 
BMD Measurements
All 74 patients participated in the 3 study visits (baseline, first follow-up, and second follow-up), during which they underwent DXA scans for estimation of areal BMD (g/cm 2 ), bone mineral content (g), and bone area (BA, cm 2 ) in the whole body, lumbar spine (L1-L4), and total hip. The DXA measurements were all performed at the Sahlgrenska University Hospital in Gothenburg (Sweden). For the baseline and first follow-up measurements, we used the Lunar densitometer (DPX-IQ version 4.7e; GE Medical Systems Lunar, Madison, WI), with Lunar software ver. 4.7; the data for these measurements have previously been published. 1, 2 For the second follow-up, we used the Lunar Prodigy DXA (GE Medical Systems Lunar). This DXA machine was also used for measurements of the previously published local male references from the "GOOD study." 16 The correlation between the DPX-IQ and Prodigy DXA machines has been found to be very strong at different measurement sites (R ¼ 0.98-0.99). 23 The BMD, bone mineral content, and BA values for females and males are expressed as absolute values. BMD is also expressed as a Zscore (compared with the DXA manufacturer's standard reference) or local male Z-score (compared with local reference material, as described below). The BMD Z-score for the total hip could not be calculated at the first follow-up relative to the standard references because of the lack of reference data from the manufacturer.
PBM has been defined according to Baxter-Jones et al 15 as occurring 5 years after PHV in the lumbar spine and total hip, and 7 years after PHV in the whole body.
Healthy Reference Groups
To ensure a reliable comparison of BMD in our cohort of patients with childhood-onset IBD, we used 2 reference groups for BMD: a normative reference database, which we refer to here as "standard references" and an age-matched male reference group from the same catchment area, which we refer to as "local male references." 16 For the height Z-score, weight Z-score, and PHV, we also used 2 reference populations for comparison: "the national Swedish references," 22, 24 on which the growth charts are based, and "local male references." 16 The references used in this study are described in detail below.
Standard References for Comparisons of BMD
The normative healthy reference database, which uses sex, weight, ethnicity-and age-specific reference data, is provided by the DXA machine manufacturer LUNAR (GE Medical Systems Lunar).
Local Male References for Comparisons of BMD, Height, Weight, and PHV To further validate our results, we used the available reference group of healthy males. Our research team has previously performed the GOOD study, 16 which looked at BMD in healthy young males (N ¼ 1068; age range, 18-25 yr, i.e., belonging to the same generation as our study participants) from the Gothenburg region. 16, 25 To generate an age-matched reference group, the 128 youngest participants from the GOOD study were excluded. The remaining 940 participants in the GOOD study cohort served as the "local male references" in this study. The calculations of local male BMD Z-scores, local male height Z-scores, and local male weight Z-scores, and the comparisons of the BMD values and PHV were based on this reference group. No corresponding reference groups for healthy females from the area were available.
National References for Comparisons regarding Height, Weight, and PHV We used the current Swedish national standards for growth monitoring and evaluation as the references for height, weight, and PHV. 22, 24 For women, the reported mean height was 167.59 (66.08 SD) cm and the mean bodyweight at 18 years of age was 61.29 (68.65 SD) kg. For men, the reported mean height was 180.43 (66.58 SD) cm and the mean weight at 18 years of age was 72.24 (4 SD) kg. 24 Z-score was calculated for each patient's height and weight based on the national reference data using the formula for Z-scores and SD (Z ¼ [measured value2reference group mean]/reference group SD). The mean age at PHV was 11.6 years for females and 13.5 for males, with 1 year SD for both sexes. 22 
Statistical Analysis
Statistical analysis was performed with the SPSS software ver. 22 (IBM Corp., Armonk, NY). Differences between groups for continuously distributed variables were evaluated using analysis of variance, followed by a multiple variance test or t test. Categorical variables were analyzed with a x 2 test. Comparison of the differences between study visits was performed using paired t test. When appropriate, the statistical significance of the findings was corroborated using nonparametric analogs. We tested with a single sample t test whether the standard reference BMD Z-scores differed significantly from the reference population mean Z-score of zero. All tests are 2-tailed and all significance tests used a significance level of ,0.05. According to sample size calculations, we would need at least 31 patients for adequate power to find a clinically relevant Z-score difference of 0.5 SD. The single case of IBD-U was excluded from evaluation for differences between disease subcategories due to the low number of cases.
For the univariate multivariable regressions, the whole-body BMD Z-score and the lumbar spine BMD Z-score at the second follow-up were dependent variables. The primary predictors were as follows: BMD Z-score at baseline; sex; weight at second followup; and the average parental BMD Z-score (previously published by our group 19 ). The secondary predictors were as follows: age at second follow-up; height Z-score at second follow-up; ever having received treatment with biological agents: azathioprine, 5-ASA, or prednisolone; disease subcategory; age at diagnosis; and the difference between bone age and chronologic age (DBA-CA) at baseline measurement. The regression model was built using a stepwise approach. The final model included the primary predictors of age at diagnosis, treatment with prednisolone, and biological agents at any time before the second follow-up, and a total of 7 covariates with 73 observations (1 patient was excluded because of missing parental BMD data). Other treatment regimens, such as azathioprine and 5-ASA, along with age at the second follow-up, height Z-score, disease subcategory, and difference between bone age and chronologic age (DBA-CA) at baseline measurement, were not significant predictors or confounders and did not improve the model. The results are provided as unstandardized B-values and a P-value ,0.05 was considered statistically significant.
Ethical Considerations
Informed consent was obtained from all the participants. The study was approved by the Ethical Review Committee of the University of Gothenburg (Sweden) (application numbers 182-02 and 117-11).
RESULTS
Patients' Characteristics
At the time of the second follow-up in this longitudinal study, 74 young adults with childhood-onset IBD had been prospectively followed for a mean period of 8. . Current treatment with azathioprine was present in 24 (33%) of the patients and 55 (74%) had ever been treated with the drug. In total, 74 (100%) patients had received 5-ASA treatment and 41 (55%) had an ongoing treatment with 5-ASA medication. A substantial proportion of the patients had ever been treated with biological agents (N ¼ 16 [22%]) and 7 (9%) were currently on biologics (Table 1) . Only 2 (3%) of the UC patients had ever received methotrexate and 1 (1%) CD patient was currently on methotrexate.
Interestingly, 14 patients (19%) had no current medical treatment, although all of them had received medical treatment previously: prednisolone, N ¼ 12 (86%); azathioprine, N ¼ 11 (86%); 5-ASA medication, N ¼ 4 patients (29%); and biological medication, N ¼ 0 (0%). Furthermore, 9 of the 14 patients (64%) had received surgical treatment for IBD, which might be the reason why they had no current medical treatment.
Longitudinal Development of BMD in Young Adults with Childhood-onset IBD
At the second follow-up in young adulthood, a high percentage of our patients had low BMD Z-scores in the lumbar spine (L1-L4), such that 33.8% (N ¼ 25) had a BMD Z-score of less than 21 SD and 9.5% (N ¼ 7) had a BMD Z-score of less than 22 SD. In comparison, for the standard reference group the expected proportions of individuals with lumbar spine BMD Z-scores lower than 21 SD and 22 SD are 15.6% and 2.2%, respectively.
The group of patients with CD had a significantly lower mean BMD Z-score for the lumbar spine at 20.64 (61. 13 Table 2 .
Regarding the longitudinal development of BMD, we observed a significant increase in the whole group of patients with IBD for the mean lumbar spine BMD Z-score: from 20. respectively. The development of BMD for total hip could not be evaluated because no data on the BMD for total hip were available for standard references at the first follow-up, which made it impossible to calculate the BMD Z-score.
Regarding the IBD subcategories, a significant increase in the mean lumbar spine BMD Z-score was observed for the patients with UC: from 20. Next, we looked at whether there was any sex difference with regard to BMD development in our cohort of patients with IBD. The longitudinal development of BMD in the female and male patients is shown as the absolute BMD values for the lumbar spine and total hip in Figure 2A 
Bone Mineralization Continues in the Lumbar Spine Past the Expected Age for Attaining PBM in Young Adults with Childhoodonset IBD
We performed a subgroup analysis of those patients who were expected to have achieved PBM at baseline or at the first follow-up based on the time that had elapsed since PHV (see Patients and Methods section). Seven female patients and 10 male patients fulfilled these criteria for the achievement of PBM in the lumbar spine and total hip before the second follow-up. Notably, at the second follow-up in young adulthood, significant increases in BMD and BMD Z-scores were observed for the lumbar spine in the female patients and male patients (Table 4) . Furthermore, an increase of BMD in the total hip was seen in the female patients, whereas in the male patients, a significant loss of BMD in the total hip was observed (Table 4) . Because of the low number of patients who fulfilled the criteria for having achieved PBM in the whole body at baseline or at the first follow-up (3 females and 3 males), it was not possible to draw any conclusion regarding the development of whole-body BMD over time.
Growth and Puberty
Young male patients with childhood-onset IBD (N ¼ 49 [66%]) had a lower mean height of 177.9 cm (6 5.8 SD, range [161.6-188.9]) than the national reference height of 180.4 cm (66.6 SD, P ¼ 0.004). The male IBD patient group's mean height Z-score was 20.38 (60.9 SD, range [22.9 to 1.3], P ¼ 0.004), as compared to the national references. A similar difference, albeit more pronounced, was found when the male patients with IBD were compared with the local male references, who had a mean height of 181.9 cm (66.8 SD, range [162.6-204.5], P , 0.001). In contrast, the female patients with IBD had a mean height of 166.1 cm (67.4 SD, range [152.6-180.2]), which was similar to the national references height of 167.6 cm (66 SD, P ¼ 0.334). The female IBD patient group's mean height Z-score was 20.24 (61.2 SD, range [22.5 to 2.1], P ¼ 0.338), as compared to the national references (Table 1 ). There was no significant correlation between delayed bone age at baseline and height Z-score at the second follow-up in either the females (R ¼ 20.23, P ¼ 0.278) or males (R ¼ 0.12, P ¼ 0.436).
Furthermore, we compared the parentally predicted TH with the height at the second follow-up in young adulthood. The vertical dotted line indicates the mean age for expected attainment of peak bone mass in both the lumbar spine and total hip, 5 years after the mean peak height velocity in our cohort (17.1 yrs in females and 18.6 yrs in males). The solid blue line represents a second-order polynomial nonlinear curve estimation, and the dotted red lines represent the 95% confidence interval.
13.7])
. Only 2 males with CD had height Z-scores of 22.9 (TH Z-score ¼ 22.9) and 22.1 (TH Z-score ¼ 20.1 SD), respectively, and 1 female with UC had a height Z-score of 22.5 (TH Z-score ¼ 20.9SD), thereby fulfilling the criterion for "growth restriction" with a height Z-score of less than 22 SD. The average mean patient height Z-score correlated significantly with the average mean parental height Z-score (R ¼ 0.664, P , 0.001).
The bodyweights of the young adult patients with childhood-onset IBD, both males and females, did not deviate significantly from those of the national reference population (Table 1) Furthermore, we evaluated whether the patients with CD and the patients with UC differed at the second follow-up regarding height, height Z-scores, weight, weight Z-scores, and body mass index. No significant differences in these parameters were found between the 2 diagnostic groups.
PHV was calculated for 43 participants (58%) for whom sufficient data were available from their growth charts (Table 1) The PHV data from both the female and male patient groups exhibited a normal Gaussian distribution. The age at PHV did not differ between the cases of CD and UC. Furthermore, there were no significant differences with regards to age, weight, height, and BMD at the second follow-up between those with calculable PHV and those without PHV data. 
Predicting Factors for BMD in Young
DISCUSSION
In this prospective longitudinal study of BMD development, we followed patients with childhood-onset IBD from childhood through adolescence to early adulthood for an average period of 8 years. This cohort of patients represents the entire clinical spectrum of childhood-onset IBD, including patients with mild and moderate as well as severe disease course. There are only limited data available on the evolution of BMD in patients with childhood-onset IBD into young adulthood. 1, 17 At follow-up in young adulthood, we found that the male patients with childhood-onset IBD had both compromised BMD and reduced height. In contrast, the female patients had BMD and height values that lay in the same range as the standard and national references, respectively. No significant difference in BMD was found between patients with CD and patients with UC. The BMD Z-score for the lumbar spine improved in the group of all IBD patients between the first and second follow-up visits, even in those individuals who were expected to have achieved PBM at baseline or at the first follow-up visit.
Male patients with IBD in young adulthood had lower BMD than local male references at all 3 measurement sites (lumbar spine, total hip, and whole body). A similar outcome was found when comparing these results to standard references provided by the LUNAR manufacturer. These findings of low BMD in young adulthood are in line with the previous report of Laakso et al. 17 They are also supported by the observation that middle-aged men with IBD develop osteoporosis more frequently than women (55.9% versus 29.6%). 9 Despite the fact that the male patients improved their BMD Z-scores in the lumbar spine between the first and second follow-up visits, as compared to the standard references, this did not translate into complete catch-up for the BMD in the lumbar spine in young adulthood. In contrast to the increase in BMD in the lumbar spine, the male patients showed a decrease in total hip BMD during the follow-up period into young adulthood. However, a similar pattern of reduction in BMD in the total hip over time in young adulthood has been seen in healthy individuals. 25 Unlike the situation in the male patients, the female patients with IBD had BMD values at all the measurement sites (lumbar spine, total hip, and whole body) that were in the same range as those of the standard references, at the second follow-up in young adulthood. Similar to the male patients, females continued to show improvements in their lumbar spine BMD Z-scores into young adulthood, as compared to the standard references. In contrast to the males, the females increased their BMD Z-scores also in the total hip into young adulthood, whereby the corresponding BMD in healthy individuals would be stable over time. 15 These findings of normal BMD Z-scores in female patients with IBD are in line with a previous report that showed low prevalence of osteoporosis in premenopausal women with childhood-onset IBD. 26 The findings that both females and males with IBD continued to improve their lumbar spine BMD Z-scores into young adulthood, as compared to the standard references, have to our knowledge not been described previously for this patient group. However, these findings are in accordance with our previous observation that adolescents aged between 17 and 19 years tended to increase their BMD scores for the lumbar spine after 2 years of follow-up. 1 To investigate whether the patients with childhood-onset IBD continued to improve their BMD beyond the supposed age of PBM attainment, we used the model described by Baxter-Jones et al. 15 Based on this model, a fixed time span between PHV and PBM exists in healthy individuals (5 years for lumbar spine/total hip and 7 yrs for whole body). Interestingly, we found that a substantial proportion of our patients continued to improve their bone mineralization levels in the lumbar spine several years after the expected age for PBM, and female patients showed improvements even in the total hip after the expected achievement of PBM. The mechanisms underlying the improvement in BMD beyond the expected time of PBM achievement remain unclear. Additional studies are needed to investigate in greater detail the timing of PBM in patients with childhoodonset IBD, as our data indicate PBM may occur, at least in some patients, later in this patient group than in healthy individuals.
The clinical relevance and implications of our main findings have to be considered. An interesting observation was that young adult patients with childhood-onset IBD, both male and female, seem to have the capacity to improve their BMD beyond what is generally expected. This finding may be valuable for the management of these patients with a chronic inflammatory disorder and concurrent compromised BMD. Thus, young adulthood can be seen as a window of opportunity, within which period it is still highly meaningful to instigate measures to increase BMD and treat known risk factors, e.g., ongoing inflammation. 12, 13 This may also form the basis for a promising approach to BMD development when informing these patients. However, despite this capacity for BMD improvement, the male patients with IBD in young adulthood run an increased risk of having compromised BMD, in that they displayed a decreased mean Z-score for the lumbar spine of -0.8 SD and for the total hip of 20.5 SD, which we consider clinically relevant as it is more than 0.5 SD distant from the population as a whole. Provided that no improvement in bone density occurs in the long term, this may result in an increased risk of fractures. It has been reported that the relative risk of fracture in late adulthood is 2 to 3 for each 1 SD decrease of BMD. 27 In summary, our data underline the importance of maintaining the focus on treatments that promote BMD development in young adulthood, especially for young adult male patients.
Using a multivariable linear regression model, we identified several independent predictors of BMD Z-scores in young adulthood. Young age at diagnosis was an independent predictive factor for low BMD Z-scores in both the whole body and lumbar spine. This leads us to speculate that this parameter reflects longstanding inflammation, which can subsequently have a negative effect on BMD development. 12 In accordance with this, long duration of disease in adults with IBD has been reported as an independent predictor of low BMD in adulthood. 7 Treatment with biologics showed a trend (P ¼ 0.084) toward predicting a lower whole-body BMD Z-scores in the model, so one might consider it to be a surrogate marker of disease course severity in our cohort. In Sweden, almost all patients are treated according to the national treatment protocol for pediatric IBD, which is in line with international recommendations. 28, 29 Biologics are used in a "step-up strategy," which is used when inflammation control cannot be achieved through treatment with other agents, such as prednisolone, 5-ASA, and azathioprine. On the contrary, beneficial effects on BMD of biological medications have been described in both children 12 and adults. 30 Prednisolone treatment showed a similar trend toward predicting a low wholebody BMD Z-score (P ¼ 0.052), which is not surprising as long-standing use of prednisolone has negative effects on BMD development and has previously been reported as a risk factor for children with IBD. 13 Collectively, these observations may point to the important role of chronic inflammation in BMD development in childhood-onset IBD.
Male patients with childhood-onset IBD had compromised height, as compared to both the local male references and the national references. 24 We also found that the male patients had no delay in age at PHV as an indicator of puberty onset, when compared with either the local male references or national references. 22 In accordance with this, observations of a moderate reduction in height and the absence of delayed puberty in male patients with childhood-onset IBD, especially CD, have recently been described. 31 Furthermore, male sex has previously been identified as a risk factor for growth impairment in cases of childhood-onset IBD. 32 Notably, our group of female patients had a mildly decreased height Z-score and a slightly delayed age of PHV (6 mo on average) as an indicator of puberty onset, as compared to the national references. 24 The almost normal height of the female patients might be explained by the recent observation that a slightly delayed PHV in healthy females may prolong the time span for linear growth. 33 Growth restriction (height Z-score ,22SD) was found in about 4% of the patients in our cohort, which is similar to what one expects in a normal population (approximately 2%). These low growth restriction rates in young adulthood contrast with previously reported growth failure in 19% to 35% of patients with childhoodonset IBD in young adulthood, mainly in patients with CD. 34 The strength of this study is the longitudinal follow-up, extending over more than 8 years, of a cohort of patients with childhood-onset IBD, which allowed us to follow these patients into young adulthood. To our knowledge, this is currently the longest follow-up study of BMD development in patients with childhood-onset IBD. Another strength is that the cohort represents the entire clinical spectrum of pediatric IBD in a defined catchment area. Our study also provides the unique opportunity to take parental BMD and height Z-scores into account. Furthermore, we were able to validate the BMD data for our male patients using an additional local age-matched reference population for male patients. Unfortunately, no such reference group was available for females in our area. Despite this limitation, we consider the standard references used routinely in clinical practice to be adequate for the purpose of comparison. In support of this notion, we found the results for the male patients with IBD to be similar regardless of whether we compared them with the local or standard references. A limitation of this study is the relatively high proportion of nonparticipants in the second follow-up. However, no significant differences were found for a number of key parameters, including BMD, age, height, weight, disease subcategory, and medication, between the participants and nonparticipants. Therefore, we believe that the study population is representative for our cohort of young adult patients with childhood-onset IBD. An additional limitation is that we do not have PHV calculations for all the participants (58%); there were however no significant differences with regards to age, weight, height, and BMD at the second follow-up between those with calculable PHV and those without PHV data.
In summary, our findings show that young adult male patients with childhood-onset IBD have increased risks of compromised BMD and reduced height. In contrast, female patients with childhood-onset IBD seem to have BMD and height values within the normal ranges. Furthermore, our data suggest that young adult patients with IBD have the potential to improve their levels of bone accumulation beyond the expected time for achieving PBM.
